Suppr超能文献

依帕司他对大鼠晶状体渗透压膨胀的抑制作用

[Inhibition effect of epalrestat on rat lens osmotic expansion].

作者信息

Ji Li-Xia, Shen Ning, Li Cai-Na, Liu Quan, Huan Yi, Shen Zhu-Fang

机构信息

Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

出版信息

Yao Xue Xue Bao. 2009 Oct;44(10):1107-11.

Abstract

Epalrestat is the unique aldose reductase inhibitor on the market, which was mainly used for the diabetic neuropathy. Lenses osmotic expansion could be induced by galactose to mimic the pathological process of diabetic cataract in vitro. In present study, we mainly investigated whether epalrestat possesses inhibitory effect on the lens osmotic expansion. The results indicated that epalrestat could not only markedly inhibit rat lens osmotic expansion in vitro, but also significantly reduced the high expression of the osmotic expansion-related genes such as AR and AQP1 in mRNA and protein levels. The findings may provide an important reference to epalrestat in the clinical application for the treatment of diabetic cataract.

摘要

依帕司他是市面上唯一的醛糖还原酶抑制剂,主要用于治疗糖尿病性神经病变。半乳糖可诱导晶状体渗透压升高,在体外模拟糖尿病性白内障的病理过程。在本研究中,我们主要探讨依帕司他是否对晶状体渗透压升高具有抑制作用。结果表明,依帕司他不仅能在体外显著抑制大鼠晶状体渗透压升高,还能在mRNA和蛋白质水平上显著降低渗透压升高相关基因如AR和AQP1的高表达。这些发现可能为依帕司他在糖尿病性白内障临床治疗中的应用提供重要参考。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验